<?xml version="1.0" encoding="UTF-8"?>
<p>Apart from this, the lack of participation and an insufficient amount of pronounced repositioning projects, especially from big renowned pharmaceutical companies contribute a significant challenge in drug repositioning. This scenario is due to the lack of faith in prospective projects, the likelihood of failure and huge time and money investment in these projects. Interestingly, the role of drug repositioning was mostly initiated by companies other than the primary inventor [
 <xref rid="B110-viruses-12-01058" ref-type="bibr">110</xref>]. For example, Thalidomide, a complete failure in drug development history was brought back to life by the company Celgene to treat Multiple Myeloma Nodosum Leprosum and Erythema with the exclusion of pregnant women, but not by the inventor company Gr√ºnenthal [
 <xref rid="B73-viruses-12-01058" ref-type="bibr">73</xref>,
 <xref rid="B112-viruses-12-01058" ref-type="bibr">112</xref>,
 <xref rid="B114-viruses-12-01058" ref-type="bibr">114</xref>].
</p>
